Clinical Trials Directory

We are doing this study to compare the outcomes of 2 treatments for women with stress urinary incontinence (SUI): transurethral bulking agent (TBA) and single-incision sling (SIS). Both treatments are FDA-approved and can help improve SUI symptoms, but they have not been directly compared to each other to see which treatment is better for certain patients and under what circumstances. We hope this study can help women and their doctors find out which option is most likely to have the best results. Current evidence suggests that TBA and SIS are less effective than a traditional full-length mid-urethral sling procedure, but both options are less invasive and less likely to cause complications afterward.

We are doing this study to find out whether certain immunotherapy drug combinations with and without chemotherapy given before and after surgery for mesothelioma can help prevent the tumor from coming back. The two immunotherapy drugs, durvalumab and tremelimumab, are called immune checkpoint inhibitors and are used to activate the immune system against cancer. Immune checkpoint inhibitors are now approved for mesothelioma for patients who cannot undergo surgery, but they are not approved prior to surgery. The chemotherapy drugs (cisplatin or carboplatin and pemetrexed) are standard options for the treatment of mesothelioma.

We are doing this study to find out if an investigational drug called TP-3654 (the study drug) is a safe and effective treatment for myelofibrosis. The study drug will be tested at different doses to find out what effects, if any, it has on myelofibrosis.

This study has two parts. In the first part, researchers test different dose levels of a new medicine called BBO 11818 to find the safest and best dose. Some people will receive BBO 11818 by itself, while others will receive it together with other cancer medicines. The treatment group depends on the type of cancer and the specific KRAS gene change a person has. In the second part, more people will receive the dose that was found to be safe in the first part. Researchers will study BBO 11818 by itself and in combination with other treatments in different groups of patients. The goal is to learn more about how safe the medicine is, what side effects it may cause, and whether it can help slow or shrink cancers with specific KRAS gene changes.

Participants will complete various surveys about their health and experience with their new bowel program.

If you join the study, you will be placed into one of two treatment groups. One group will get a sling called a retropubic mid-urethral sling (RP-MUS). The other group will get a treatment called urethral bulking with a gel called polyacrylamide gel (PAHG). After the procedure, you will have check-up visits at 1 month, 6 months, 12 months, and 24 months. You can also choose to take part in interviews about your experience.

You will be randomly assigned to one of two study arms: • Arm A: Sonrotoclax + Zanubrutinib • Arm B: Venetoclax + Acalabrutinib The study includes Screening (up to 35 days), Study Treatment, and Follow‑up. Screening involves exams, blood tests, heart tests, and imaging. Treatment includes oral medications with ramp‑up dosing schedules and regular monitoring.